ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects

Phase 2

Withdrawn

Conditions: HIV Infection
Hepatitis C

First Posted Date: 2005-07-21

Last Posted Date: 2006-07-27

Lead Sponsor: Abbott

Target Recruit Count: 200

Registration Number: NCT00121017

Endometriosis Trial: Study of NBI-56418 in Endometriosis

Phase 2

Completed

Conditions: Endometriosis

Interventions: Drug: placebo
Drug: NBI-56418 (GnRH antagonist)

First Posted Date: 2005-04-29

Last Posted Date: 2012-02-22

Lead Sponsor: Abbott

Target Recruit Count: 76

Registration Number: NCT00109512

Locations: 🇺🇸
Site Reference ID/Investigator# 56269, Oak Brook, Illinois, United States
🇺🇸
Site Reference ID/Investigator# 55214, San Ramon, California, United States
🇺🇸
Site Reference ID/Investigator# 56271, Peoria, Illinois, United States

and more 12 locations

Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

First Posted Date: 2005-03-14

Last Posted Date: 2006-08-15

Lead Sponsor: Abbott

Target Recruit Count: 300

Registration Number: NCT00105300

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
SMC-Trauma Research, Englewood, Colorado, United States
🇺🇸
Gastroenterology Associates of Cleveland, Mayfield Heights, Ohio, United States

and more 53 locations

A Study for Treatment of Partial Seizures in Children

Phase 3

Completed

Conditions: Partial Seizures

First Posted Date: 2005-02-02

Last Posted Date: 2007-05-21

Lead Sponsor: Abbott

Target Recruit Count: 50

Registration Number: NCT00102713

Locations: 🇺🇸
Akron Children's Hospital, Akron, Ohio, United States
🇺🇸
Richard V. Colan, M.D., S.C., Milwaukee, Wisconsin, United States
🇺🇸
University Hospitals of Cleveland, Cleveland, Ohio, United States

and more 7 locations

Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)

Phase 2

Terminated

Conditions: Renal Cell Carcinoma
Metastases

Interventions: Drug: Volociximab (anti-α5β1 integrin monoclonal antibody)

First Posted Date: 2005-01-05

Last Posted Date: 2012-04-27

Lead Sponsor: Abbott

Target Recruit Count: 48

Registration Number: NCT00100685

Locations: 🇺🇸
Site Reference ID/Investigator# 70400, Los Angeles, California, United States
🇺🇸
Site Reference ID/Investigator# 70399, Cleveland, Ohio, United States
🇺🇸
Site Reference ID/Investigator# 70401, New York, New York, United States

Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis

Phase 3

Completed

Conditions: Kidney Disease

First Posted Date: 2004-09-22

Last Posted Date: 2011-01-19

Lead Sponsor: Abbott

Target Recruit Count: 78

Registration Number: NCT00091975

Locations: 🇺🇸
St. Louis University, St. Louis, Missouri, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
University of Florida, Gainesville, Florida, United States

and more 13 locations

Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis

Phase 4

Completed

Conditions: Kidney Failure, Chronic

First Posted Date: 2004-09-13

Last Posted Date: 2007-09-26

Lead Sponsor: Abbott

Target Recruit Count: 201

Registration Number: NCT00091481

Locations: 🇬🇷
General Hospital of Heraklion, Voutes, Heraklion, Crete, Greece
🇬🇷
General Hospital of Melissia "Amalia Fleming", Melissia, Athens, Greece
🇬🇷
General University Hospital of Alexandroupolis, Dragana, Greece

and more 16 locations

Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

Phase 3

Completed

Conditions: Ankylosing Spondylitis

Interventions: Biological: adalimumab (D2E7)
Biological: placebo

First Posted Date: 2004-06-16

Last Posted Date: 2011-04-21

Lead Sponsor: Abbott

Target Recruit Count: 315

Registration Number: NCT00085644

Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

First Posted Date: 2004-02-16

Last Posted Date: 2007-09-26

Lead Sponsor: Abbott

Target Recruit Count: 854

Registration Number: NCT00077779

Locations: 🇺🇸
Gastroenterology Associates of Fairfield County, Bridgeport, Connecticut, United States
🇺🇸
Clinical Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸
Mark Lamet, MD, Hollywood, Florida, United States

and more 40 locations

A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2004-01-08

Last Posted Date: 2006-10-02

Lead Sponsor: Abbott

Target Recruit Count: 150

Registration Number: NCT00075231

Locations: 🇺🇸
Fountain Valley Regional Hospital and Medical Center, Fountain Valley, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy